March 8, 2018 08:00 AM EST
R&D

Fail­ure in piv­otal PhI­II brain can­cer tri­al drags Is­rael's VBL Ther­a­peu­tics down

Amber Tong

VBL Ther­a­peu­tics $VBLT is in cri­sis mode this morn­ing af­ter it an­nounced that its lead drug flunked a Phase III study in brain can­cer. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

A service from the Financial Times